The FDA cleared orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, based on the ATTAIN clinical program which showed placebo-adjusted weight loss of 7.5% to 11.2% in non-diabetics (ATTAIN-1) and 5.1% to 9.6% in diabetics at different doses, along with the expected glycaemic benefits (ATTAIN-2)
We are talking about deep discounts on essential fertility drugs
Table 15: Analysis of the Composite 3-point MACE and Individual Cardiovascular Endpoints in DEVOTE * PYO = patient-years of observation until first MACE, death, or trial discontinuation Figure 3: Cumulative Event Probability for Time to First MACE in DEVOTE Hypoglycemia Outcomes - Patients with T2DM and Atherosclerotic CVD The pre-specified secondary endpoints of event and incidence rates of severe hypoglycemia were sequentially tested
GLP-1 receptor agonists enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic signaling [10]
Clin Exp Pharmacol Physiol 42(6):632639
